Please login to the form below

Not currently logged in
Email:
Password:

solanezumab

This page shows the latest solanezumab news and features for those working in and with pharma, biotech and healthcare.

Eli Lilly shutters UK neuroscience unit, with 80 job losses expected

Eli Lilly shutters UK neuroscience unit, with 80 job losses expected

Its pipeline currently includes solanezumab for Alzheimer’s – which has already failed earlier phase 3 trials – along with two antibodies for the disease in mid-stage testing (donanemab and zagotenemab) and

Latest news

More from news
Approximately 5 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    Lilly said that while the study results, ‘including many secondary clinical endpoints, directionally favoured solanezumab, the magnitudes of treatment differences were small’. ... December, where Lilly confirmed it will not pursue regulatory

  • Interview: Mike Hutton, Lilly Interview: Mike Hutton, Lilly

    Lilly's great hope in amyloid beta is now solanezumab, a candidate with a chequered history. ... But Lilly is pressing on with a third late-stage trial, and Dr Hutton was adamant solanezumab remains a priority project for Lilly. .

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...

Infographics